Axsome Therapeutics (AXSM) Profit After Tax (2015 - 2026)

Axsome Therapeutics has disclosed Profit After Tax across 12 years of filings, most recently posting -$64.5 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$64.5 million, down 8.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$188.3 million (up 32.33% YoY), and the FY2025 annual result was -$183.2 million, up 36.22% from the prior year.
• Profit After Tax came in at -$64.5 million for Q1 2026 at Axsome Therapeutics, down from -$28.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$11.2 million in Q1 2023 to a low of -$98.7 million in Q4 2023.
• The 5-year median for Profit After Tax is -$61.2 million (2022), against an average of -$56.5 million.
• Across the five-year window, Profit After Tax jumped 71.69% in 2023 and sank 509.35% in 2024, its largest moves.
• Axsome Therapeutics' Profit After Tax stood at -$61.2 million in 2022, then slumped by 61.09% to -$98.7 million in 2023, then rose by 24.06% to -$74.9 million in 2024, then surged by 61.88% to -$28.6 million in 2025, then plunged by 126.0% to -$64.5 million in 2026.
• The last three Profit After Tax figures came in at -$64.5 million (Q1 2026), -$28.6 million (Q4 2025), and -$47.2 million (Q3 2025), per Business Quant data.